Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
Phase II: To evaluate the rate of patients alive and progression free at 6 months, assessed by the investigator according to RECIST criteria, version 1.1. Phase III: To assess and compare the Progression Free Survival (PFS) of lanreotide versus placebo according to RECIST criteria (version 1.1, Appendix 3), assessed by the investigator.
Inclusion criteria
- Non-resectable duodeno-pancreatic neuroendocrine tumours after first line treatment